256 related articles for article (PubMed ID: 30457982)
1. PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.
Dong S; Harrington BK; Hu EY; Greene JT; Lehman AM; Tran M; Wasmuth RL; Long M; Muthusamy N; Brown JR; Johnson AJ; Byrd JC
J Clin Invest; 2019 Jan; 129(1):122-136. PubMed ID: 30457982
[TBL] [Abstract][Full Text] [Related]
2. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
Front Immunol; 2018; 9():332. PubMed ID: 29535720
[TBL] [Abstract][Full Text] [Related]
3. The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells.
Liu D; Zhang T; Marshall AJ; Okkenhaug K; Vanhaesebroeck B; Uzonna JE
J Immunol; 2009 Aug; 183(3):1921-33. PubMed ID: 19596993
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.
Khadem F; Mou Z; Liu D; Varikuti S; Satoskar A; Uzonna JE
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2951. PubMed ID: 24945303
[TBL] [Abstract][Full Text] [Related]
5. Hepatic stellate cells regulate liver immunity to visceral leishmaniasis through P110δ-dependent induction and expansion of regulatory T cells in mice.
Khadem F; Gao X; Mou Z; Jia P; Movassagh H; Onyilagha C; Gounni AS; Wright MC; Uzonna JE
Hepatology; 2016 Feb; 63(2):620-32. PubMed ID: 26289140
[TBL] [Abstract][Full Text] [Related]
6. PI3K p110δ is expressed by gp38(-)CD31(+) and gp38(+)CD31(+) spleen stromal cells and regulates their CCL19, CCL21, and LTβR mRNA levels.
Zotes TM; Spada R; Mulens V; Pérez-Yagüe S; Sorzano CO; Okkenhaug K; Carrera AC; Barber DF
PLoS One; 2013; 8(8):e72960. PubMed ID: 24009720
[TBL] [Abstract][Full Text] [Related]
7. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ.
Uno JK; Rao KN; Matsuoka K; Sheikh SZ; Kobayashi T; Li F; Steinbach EC; Sepulveda AR; Vanhaesebroeck B; Sartor RB; Plevy SE
Gastroenterology; 2010 Nov; 139(5):1642-53, 1653.e1-6. PubMed ID: 20637203
[TBL] [Abstract][Full Text] [Related]
8. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
9. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury.
Bilancio A; Rinaldi B; Oliviero MA; Donniacuo M; Monti MG; Boscaino A; Marino I; Friedman L; Rossi F; Vanhaesebroeck B; Migliaccio A
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28851839
[TBL] [Abstract][Full Text] [Related]
11. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
Reinart N; Nguyen PH; Boucas J; Rosen N; Kvasnicka HM; Heukamp L; Rudolph C; Ristovska V; Velmans T; Mueller C; Reiners KS; von Strandmann EP; Krause G; Montesinos-Rongen M; Schlegelberger B; Herling M; Hallek M; Fingerle-Rowson G
Blood; 2013 Jan; 121(5):812-21. PubMed ID: 23118218
[TBL] [Abstract][Full Text] [Related]
12. The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets.
Liu D; Uzonna JE
J Immunol; 2010 Mar; 184(6):3098-105. PubMed ID: 20154209
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8
Spinelli L; Marchingo JM; Nomura A; Damasio MP; Cantrell DA
Front Immunol; 2021; 12():691997. PubMed ID: 34220851
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of Phosphatidylinositol 3-Kinase δ Signaling Leads to Diminished Numbers of Regulatory T Cells and Increased Neutrophil Activity Resulting in Mortality Due to Endotoxic Shock.
Okeke EB; Mou Z; Onyilagha N; Jia P; Gounni AS; Uzonna JE
J Immunol; 2017 Aug; 199(3):1086-1095. PubMed ID: 28659355
[TBL] [Abstract][Full Text] [Related]
15. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells.
Okkenhaug K; Patton DT; Bilancio A; Garçon F; Rowan WC; Vanhaesebroeck B
J Immunol; 2006 Oct; 177(8):5122-8. PubMed ID: 17015696
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse.
Hu X; Li J; Zhang Q; Zheng L; Wang G; Zhang X; Zhang J; Gu Q; Ye Y; Guo SW; Yang X; Wang L
Sci Rep; 2016 Jun; 6():28201. PubMed ID: 27306493
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Ali K; Soond DR; Pineiro R; Hagemann T; Pearce W; Lim EL; Bouabe H; Scudamore CL; Hancox T; Maecker H; Friedman L; Turner M; Okkenhaug K; Vanhaesebroeck B
Nature; 2014 Jun; 510(7505):407-411. PubMed ID: 24919154
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of PI3Kδ induces vascular injury and promotes aneurysm development by upregulating the AP-1/MMP-12 pathway in macrophages.
Zheng L; Xing L; Zeng C; Wu T; Gui Y; Li W; Lan T; Yang Y; Gu Q; Qi C; Zhang Q; Tang F; He X; Wang L
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):368-77. PubMed ID: 25503990
[TBL] [Abstract][Full Text] [Related]
19. The PI3K p110δ regulates expression of CD38 on regulatory T cells.
Patton DT; Wilson MD; Rowan WC; Soond DR; Okkenhaug K
PLoS One; 2011 Mar; 6(3):e17359. PubMed ID: 21390257
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
